0001209191-24-004043.txt : 20240227
0001209191-24-004043.hdr.sgml : 20240227
20240227210101
ACCESSION NUMBER: 0001209191-24-004043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ASADORIAN RAFFI
CENTRAL INDEX KEY: 0001628970
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35068
FILM NUMBER: 24689747
MAIL ADDRESS:
STREET 1: C/O ACELRX PHARMACEUTICALS, INC.
STREET 2: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TALPHERA, INC.
CENTRAL INDEX KEY: 0001427925
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1850 GATEWAY DRIVE
STREET 2: SUITE 175
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-216-3500
MAIL ADDRESS:
STREET 1: 1850 GATEWAY DRIVE
STREET 2: SUITE 175
CITY: SAN MATEO
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: ACELRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080222
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-14
0
0001427925
TALPHERA, INC.
TLPH
0001628970
ASADORIAN RAFFI
C/O TALPHERA, INC.
1850 GATEWAY DRIVE, SUITE 175
SAN MATEO
CA
94404
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-02-14
4
A
0
18000
0.00
A
38291
D
Stock Option (Right to Buy)
1.03
2024-02-14
4
A
0
108000
0.00
A
2034-02-13
Common Stock
108000
108000
D
The restricted stock units shall vest in three equal consecutive annual installments on February 14, 2025, February 14, 2026 and February 14, 2027.
On February 14, 2024, the reporting person was granted an option to purchase 108,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.
/s/Martha Adler, Attorney-In-Fact
2024-02-27